CN106109245A - Cancer therapy drug that a kind of 3D of employing printing technique prepares and method - Google Patents
Cancer therapy drug that a kind of 3D of employing printing technique prepares and method Download PDFInfo
- Publication number
- CN106109245A CN106109245A CN201610675357.9A CN201610675357A CN106109245A CN 106109245 A CN106109245 A CN 106109245A CN 201610675357 A CN201610675357 A CN 201610675357A CN 106109245 A CN106109245 A CN 106109245A
- Authority
- CN
- China
- Prior art keywords
- cancer therapy
- therapy drug
- drug
- printing technique
- printer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
Abstract
The invention discloses cancer therapy drug and method that a kind of 3D of employing printing technique prepares.The present invention is by by cancer therapy drug, macromolecular material and excipient substance mix homogeneously, and the mixture obtained is extruded by extruder, obtains drug containing wire rod；Utilize the structural model of design software design cancer therapy drug, save as and can for the file format of 3D printer identification, then file be imported in 3D printer, use delamination software to carry out layered shaping；Macromolecular material and the drug containing wire rod being previously obtained are directed respectively in 3D printer, selected medicines structure model, set printing precision, speed and temperature, obtain the cancer therapy drug that 3D prints.The method is convenient and swift, simple to operate, can manufacture the tablet of different sizes and shapes according to the change design size of tablet, shape and the feature of material of weather and weather, can more effectively improve the utilization rate of medicine.
Description
Technical field
The invention belongs to cancer therapy drug preparing technical field, be specifically related to that a kind of 3D of employing printing technique prepares is anti-
Cancer drug and method.
Background technology
3D printing technique is a kind of rapid shaping technique of the most popular rise, is that a kind of greenization desktop is the most rapid-result
Shape technology, its ultimate principle is with macromolecular material as base material, uses Deformation In The Fdm Process or fused glass pellet technology, passes through
Successively printing type completes object to structure and formation.The thread macromolecular material of thermoplasticity in the molten state, is continuously extruded,
Forming profile shape thin layer after solidification, successively superposition ultimately forms product, can successively pile up and build various three-dimensionals under being accurately positioned
Object.3D printing technique is huge in biomedicine field application prospect, its rapidity being had, accuracy and to be good at making multiple
Miscellaneous shape, the characteristic of color entity make it have a very wide range of applications prospect at biomedical sector.At present, hospital uses
Chemical drugs, biological medicament, Chinese patent medicine preparation all use batch production, and pattern is single, and do not have at the aspect such as plyability, slow-releasing
The performance what is particularly pertinent.Patent 201610053263.8 elaborates that one utilizes medicated powder powder and particular adhesive to pass through
3D printing technique prepares the manufacture method of special formulation drug particles, although have on the specificity of structure and the multiplicity of medicine
Certain breakthrough, but 3D printing technique based on powder bonding technology is in the preparation of slow-releasing structure, and different materials
Combination drug prepare have on (such as double shower nozzles, the most shower nozzles carry out the composite printing of different materials to prepare medicine) bigger
Limitation, so need further to supplement with by 3D printing technique based on Deformation In The Fdm Process the method being done and
Perfect.
Summary of the invention
The primary and foremost purpose of the present invention is for the deficiencies in the prior art, it is provided that a kind of employing 3D printing technique is prepared anticancer
The method of medicine.
Another object of the present invention is to provide the cancer therapy drug obtained by said method.3D printing technique is used to prepare
Cancer therapy drug, this medicine is the shapes and sizes personalized designs of medicine according to actual needs, has long-acting slow-release effect.
The object of the invention is achieved through the following technical solutions: a kind of method that the 3D of employing printing technique prepares cancer therapy drug,
Comprise the following steps:
(1) by cancer therapy drug, macromolecular material and excipient substance mix homogeneously, mixture is obtained；
(2) mixture that step (1) obtains is extruded by extruder, obtain drug containing wire rod；
(3) utilizing the structural model of design software design cancer therapy drug, saving as can be for 3D printer identification
File format, then file is imported in 3D printer, use delamination software to carry out layered shaping；
(4) drug containing wire rod prepared by macromolecular material and step (2) is directed respectively in 3D printer, selected medicine knot
Structure model, sets printing precision, speed and temperature, obtains the cancer therapy drug that 3D prints.
In mixture described in step (1), each composition is as follows: cancer therapy drug 1～5%, macromolecule
Material 95～98.9%, excipient substance 0.1～1%；Be preferably cancer therapy drug 1～4.8%, macromolecular material 95.1～
98.9%, excipient substance 0.1%.
Cancer therapy drug described in step (1) is cancer therapy drug crystal.
The crystalline melting point of described cancer therapy drug crystal is 50～220 DEG C；It is preferably 205～213 DEG C.
Described cancer therapy drug comprises one or more in Western medicine and plant antitumor class medicine.
Described Western medicine antitumor drug includes: amycin, etoposide, cyclophosphamide, fluorouracil, busulfan, rich
Bleomycin, cyclophosphamide, vincaleucoblastine, gemcitabine, methotrexate, carboplatin, capecitabine, lomustine, hydroxyurea, suitable
Platinum, mitomycin and gefitinib.
Described plant antitumor class medicine includes: paclitaxel, docetaxel, vinorelbine, elemene, hydroxy-camptothecin
Alkali, XIAOAIPING PIAN and GANFULE PIAN etc..
Described excipient substance is preferably gamma-polyglutamic acid-benzyl ester.
The employing physical mechanical stirring that is mixed into described in step (1) mixes.
The described use batch mixer that is mixed into mixes.
The condition of described mixing is preferably the rotating speed mixing 10～15min of 100rpm.
Macromolecular material described in step (1) is Biodegradable polymer material.
Described macromolecular material is chitosan, silica gel, agar, polylactic acid (PLA), Poly(D,L-lactide-co-glycolide
(PLGA), one or more in polycaprolactone (PCL) and polyhydroxyalkanoate (PHA)；It is preferably polylactic acid.
Macromolecular material described in step (4) is Biodegradable polymer material.
Described macromolecular material is chitosan, silica gel, agar, polylactic acid (PLA), Poly(D,L-lactide-co-glycolide
(PLGA), one or more in polycaprolactone (PCL) and polyhydroxyalkanoate (PHA)；It is preferably polylactic acid-glycolic base
Acetate multipolymer.
Extruder described in step (2) is single screw extrusion machine or double screw extruder.
The preparation method obtaining described drug containing wire rod in step (2) is further comprising the steps of: from extruder out
Fused mass enters the cooling of cooling and shaping platform, obtains molding filament-type plastic；Enter back into air-dry machine water is dried up；Survey through two-way laser
Traction machine is sent into after the instrument of footpath；Last plastic wire enters torque motor coiling and obtains wire rod finished product.
When mixture step (1) obtained described in step (2) is extruded by extruder, the extrusion temperature of setting is
100～200 DEG C, engine speed is 75～180rpm, and aperture size is 1.75～5.0mm.
When described extruder is single screw extrusion machine, operating condition is as follows: 170 DEG C of head one district, machine barrel one district 180
DEG C, 178 DEG C of machine barrel two district, 180 DEG C of machine barrel three district；Engine speed is set to 180rpm.
Design software described in step (3) is preferably AutoCAD3DMax2015 software.
Structural model described in step (3) is oval shape, cylinder, cube, pyramid, spherical or annulus
Shape.
The structural model Chinese medicine volume of described design cancer therapy drug is 200～600mm3；It is preferably 310mm3。
File format described in step (3) is STL form.
Delamination software described in step (3) is preferably ezlayout_reg1.26 software.
3D printer described in step (4) is Flashmelt molding (FDM) 3D printer.
The condition of the printing described in step (4) is preferably as follows: precision is 0.2mm, and speed is 40-450mm/s, printhead
Melt temperature is 180-185 DEG C；As follows: precision is 0.2mm, speed is 250mm/s, and printhead melt temperature is 185
℃。
Medicament contg in the cancer therapy drug that 3D described in step (4) prints is 0.5-50mg/g；Be preferably 5～
25mg/g。
Cancer therapy drug described in step (4) is in being dried, preserving in gnotobasis.
A kind of cancer therapy drug, the method preparing cancer therapy drug by above-mentioned employing 3D printing technique prepares.
Compared with prior art, the present invention has the following advantages and effect:
(1), in the present invention, the cancer therapy drug with slow releasing function is prepared from by 3D rapid shaping technique, preparation technology
Convenient and swift, simple to operate, can manufacture according to the change design size of tablet, shape and the feature of material of weather and weather
The tablet of different sizes and shapes, can more effectively improve the utilization rate of medicine.
(2) present invention uses biodegradable macromolecular material to be carrier, safety non-toxic, environmental protection.
(3) present invention can realize single medicine or multi-medicament at same tablet by the specificity that structure designs
Enter the slow release effect of the different periods after human body, thus reach more preferable therapeutic effect and experience.
(4) present invention can realize the compound use of multiple different pharmaceutical matrix material, and different medicine carrying consumptive material is compound
Using, thus finally give different physical characteristics, the drug particles of different pharmaceutical releasing effect prints.
Accompanying drawing explanation
Two kinds of drug model demonstration example schematic diagrams that Fig. 1 designs for the present invention.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described in further detail, but embodiments of the present invention are not limited to this.
Embodiment 1
The cancer therapy drug that a kind of 3D prints, preparation process is as follows:
(1) utilize computer-aided design special-purpose software (AutoCAD3DMax2015), design oval many stratiforms knot
The drug particles model (Figure 1A) of structure, volume is 310mm3. this model is saved as STL formatted file, uses delamination software
(ezlayout_reg1.26) process, the final file obtaining being best suitable for printing that processes, importing 3D printer (martial prowess company
3D printer CoLiDo X3045) in.
(2) by 2.5g amycin (Wuhan great achievement medication chemistry (group) company limited of big China produces, fusing point 205 DEG C) medicine
Crystal powder and the dried granule of polyvinyl alcohol of 250g (Emma bio tech ltd, Shanghai, SIGMA model) and 0.25g
Adjuvant gamma-polyglutamic acid-benzyl ester mix homogeneously, is placed in batch mixer and arranges 100rpm operation 15 minutes；The material of mix homogeneously is thrown
Entering in SJ single-screw extruder, the temperature of single-screw extruder is set to: 170 DEG C of head one district, machine barrel one district
180 DEG C, 178 DEG C of machine barrel two district, 180 DEG C of machine barrel three district；Engine speed is set to 180rpm；From single-screw extruder out
Fused mass enter cooling and shaping platform；From cooling and shaping platform out after molding filament-type plastic enter air-dry machine water is dried up；From
Air-dry machine is then fed into traction machine through Laser Bi-direction Rod Gauge the most afterwards；Last plastic wire entrance torque motor coiling i.e. obtains and contains
There is PVA (polyvinyl alcohol) the wire rod finished product of about 1% amycin medicine.
(3) being placed in by wire rod finished product in Flashmelt molding (FDM) 3D printer, selected tablet model is oval multilamellar
Structure, the PVA consumptive material that shower nozzle 1 is carrying medicament (1% amycin) of prints odd layer, the shower nozzle 2 printing even level is without negative
The PLGA material carried, the PVA consumptive material of carrying medicament and PLGA material 1:1 in mass ratio are arranged, and design printing precision is 0.2mm/
Layer, printing speed is: 250mm/h, printhead melt temperature is 185 DEG C.Time-write interval is about 10min, and print procedure is smooth,
Obtain volume eventually and be 310mm3Oval multiple structure drug particles；The medicine of acquisition is placed in dry, gnotobasis
Preserve.
(4) this drug particles is placed in the aqueous solution (regulating pH value with HCl) that pH is 4.5, passes through uv-spectrophotometric
Meter detection amycin absorbance, result shows that the amycin ellipse multiple structure drug particles containing 0.5% is just complete through 10h
Portion discharges, and display has good slow release effect.
Embodiment 2
(1) utilize computer-aided design special-purpose software (AutoCAD3DMax2015), design inside and outside ellipse double-deck
The drug particles model (Fig. 1-B model) of structure, volume is 310mm3.This model is saved as STL formatted file, with layering
Software (ezlayout_reg1.26) processes, the final file obtaining being best suitable for printing that processes, importing 3D printer (martial prowess
Company 3D printer CoLiDo X3045) in.
(2) by 12.55g paclitaxel (Guangzhou Ai Chun Pharmaceutical Technology Co., Ltd produces, fusing point 213 DEG C) medicine crystal powder
Polyvinyl alcohol polymer granule dried with 250g and 0.25g adjuvant gamma-polyglutamic acid-benzyl ester are mixed homogeneously, and are placed in batch mixer
Arrange 100rpm to run 10 minutes；Being put into by the material of mix homogeneously in SJ single-screw extruder, single screw rod plastic squeezes
The temperature going out machine is set to: 170 DEG C of head one district, 180 DEG C of machine barrel one district, 178 DEG C of machine barrel two district, 180 DEG C of machine barrel three district；Main frame
Rotating speed is set to 180rpm；Cooling and shaping platform is entered from single-screw extruder fused mass out；Go out from cooling and shaping platform
Molding filament-type plastic after Laiing enters air-dry machine and water is dried up；It is then fed into through Laser Bi-direction Rod Gauge the most afterwards from air-dry machine
Traction machine；Last plastic wire enters torque motor coiling and i.e. obtains the PVA wire rod finished product containing about 5% taxol drug.
(3) being placed in by wire rod finished product in Flashmelt molding (FDM) 3D printer, selected tablet model is oval inside and outside
Double-decker, prints the PVA consumptive material that shower nozzle 1 is carrying medicament (5% paclitaxel) of internal layer, and the shower nozzle 2 printing outer layer is without negative
The PLGA material carried, the PVA consumptive material of carrying medicament and PLGA material 1:1 in mass ratio are arranged, and design printing precision is 0.2mm/
Layer, printing speed is: 250mm/h.Printhead melt temperature is 185 DEG C, and the time-write interval is about 10min, and print procedure is smooth,
Obtain volume eventually and be 310mm3Oval in outer double-layer structure drug particles；The medicine of acquisition is placed in dry, asepsis ring
Border preserves.
(4) this drug particles is placed in the aqueous solution that pH is 5.0, by UV spectrophotometer measuring paclitaxel extinction
Degree, in result shows about to contain 2.5% paclitaxel ellipse, outer double-layer structure drug particles the most all discharges through 14h, aobvious
Show that there is good slow release effect.
Above-described embodiment is the present invention preferably embodiment, but embodiments of the present invention are not by above-described embodiment
Limit, the change made under other any spirit without departing from the present invention and principle, modify, substitute, combine, simplify,
All should be the substitute mode of equivalence, within being included in protection scope of the present invention.
Claims (10)
1. one kind uses the method that 3D printing technique prepares cancer therapy drug, it is characterised in that comprise the following steps:
(1) by cancer therapy drug, macromolecular material and excipient substance mix homogeneously, mixture is obtained；
(2) mixture that step (1) obtains is extruded by extruder, obtain drug containing wire rod；
(3) utilizing the structural model of design software design cancer therapy drug, saving as can be for the file of 3D printer identification
Form, then file is imported in 3D printer, use delamination software to carry out layered shaping；
(4) drug containing wire rod prepared by macromolecular material and step (2) is directed respectively in 3D printer, selected medicines structure mould
Type, sets printing precision, speed and temperature, obtains the cancer therapy drug that 3D prints.
Use the method that 3D printing technique prepares cancer therapy drug the most according to claim 1, it is characterised in that: in step (1)
In described mixture, each composition is as follows: cancer therapy drug 1～5%, macromolecular material 95～98.9%, medicine
Thing adjuvant 0.1～1%.
The method that employing 3D printing technique the most according to claim 1 or claim 2 prepares cancer therapy drug, it is characterised in that: step (1)
Described in cancer therapy drug be cancer therapy drug crystal.
Use the method that 3D printing technique prepares cancer therapy drug the most according to claim 3, it is characterised in that: described is anticancer
The crystalline melting point of medicine crystal is 50～220 DEG C.
Use the method that 3D printing technique prepares cancer therapy drug the most according to claim 1, it is characterised in that:
Described cancer therapy drug comprises one or more in Western medicine and plant antitumor class medicine；
Described excipient substance is gamma-polyglutamic acid-benzyl ester；
Macromolecular material described in step (1) and step (4) is Biodegradable polymer material.
Use the method that 3D printing technique prepares cancer therapy drug the most according to claim 5, it is characterised in that:
Described Western medicine antitumor drug includes: amycin, etoposide, cyclophosphamide, fluorouracil, busulfan, rich come mould
Element, cyclophosphamide, vincaleucoblastine, gemcitabine, methotrexate, carboplatin, capecitabine, lomustine, hydroxyurea, cisplatin, silk
Rimocidin and gefitinib；
Described plant antitumor class medicine includes: paclitaxel, docetaxel, vinorelbine, elemene, hydroxy camptothecin,
XIAOAIPING PIAN and GANFULE PIAN；
Described macromolecular material is chitosan, silica gel, agar, polylactic acid, Poly(D,L-lactide-co-glycolide, polycaprolactone
With one or more in polyhydroxyalkanoate.
Use the method that 3D printing technique prepares cancer therapy drug the most according to claim 1, it is characterised in that:
The employing physical mechanical stirring that is mixed into described in step (1) mixes；
Extruder described in step (2) is single screw extrusion machine or double screw extruder；
When mixture step (1) obtained described in step (2) is extruded by extruder, the extrusion temperature of setting is 100
～200 DEG C, engine speed is 75～180rpm, and aperture size is 1.75～5.0mm；
The preparation method obtaining described drug containing wire rod in step (2) is further comprising the steps of: from extruder out melted
Thing enters the cooling of cooling and shaping platform, obtains molding filament-type plastic；Enter back into air-dry machine water is dried up；Through Laser Bi-direction Rod Gauge
Rear feeding traction machine；Last plastic wire enters torque motor coiling and obtains wire rod finished product；
3D printer described in step (4) is Flashmelt molding 3D printer；
The condition of the printing described in step (4) is as follows: precision is 0.2mm, and speed is 40-450mm/s, printhead melt temperature
For 180-185 DEG C.
Use the method that 3D printing technique prepares cancer therapy drug the most according to claim 7, it is characterised in that:
When described extruder is single screw extrusion machine, operating condition is as follows: 170 DEG C of head one district, 180 DEG C of machine barrel one district, machine
Cylinder 178 DEG C of 2nd district, 180 DEG C of machine barrel three district；Engine speed is set to 180rpm.
Use the method that 3D printing technique prepares cancer therapy drug the most according to claim 1, it is characterised in that:
Design software described in step (3) is AutoCAD3DMax2015 software；
Structural model described in step (3) is oval shape, cylinder, cube, pyramid, spherical or annular；
The structural model Chinese medicine volume of described design cancer therapy drug is 200～600mm3；
File format described in step (3) is STL form；
Delamination software described in step (3) is ezlayout_reg1.26 software.
10. a cancer therapy drug, it is characterised in that: by using the preparation of 3D printing technique anti-described in any one of claim 1～9
The method of cancer drug prepares.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610675357.9A CN106109245A (en) | 2016-08-16 | 2016-08-16 | Cancer therapy drug that a kind of 3D of employing printing technique prepares and method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610675357.9A CN106109245A (en) | 2016-08-16 | 2016-08-16 | Cancer therapy drug that a kind of 3D of employing printing technique prepares and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106109245A true CN106109245A (en) | 2016-11-16 |
Family
ID=57280209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610675357.9A Pending CN106109245A (en) | 2016-08-16 | 2016-08-16 | Cancer therapy drug that a kind of 3D of employing printing technique prepares and method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106109245A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727393A (en) * | 2016-12-26 | 2017-05-31 | 浙江工业大学 | A kind of sustained release preparations of ibuprofen containing grid internal structure and preparation method thereof |
| CN108042363A (en) * | 2018-01-17 | 2018-05-18 | 陶俊荣 | One kind can on-line checking Chinese patent medicine tablet preparation system and method |
| CN112618479A (en) * | 2020-11-20 | 2021-04-09 | 扬州大学 | Preparation method of docetaxel/polylactic acid anti-tumor implantation stent |
| CN112618922A (en) * | 2020-12-30 | 2021-04-09 | 上海心至医疗科技有限公司 | Preparation method of drug balloon, prepared drug balloon and application thereof |
| WO2022173227A1 (en) * | 2021-02-10 | 2022-08-18 | 전남대학교 산학협력단 | Method for preparing solid drug formulation on basis of ultraviolet printing |
| US11724486B2 (en) | 2019-07-09 | 2023-08-15 | Kyndryl, Inc. | Printing customized medication based on current user data and medical records of the user |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6547994B1 (en) * | 1998-11-13 | 2003-04-15 | Therics, Inc. | Rapid prototyping and manufacturing process |
| CN1732899A (en) * | 2005-06-16 | 2006-02-15 | 华中科技大学 | Implantation type local drug delivery device and three-dimensional printing preparation method thereof |
| WO2016116502A1 (en) * | 2015-01-21 | 2016-07-28 | Bayer Oy | Drug delivery system comprising a non-steroidal anti-inflammatory (nsaid) and a progestogenic compound and methods for manufacturing |
-
2016
- 2016-08-16 CN CN201610675357.9A patent/CN106109245A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6547994B1 (en) * | 1998-11-13 | 2003-04-15 | Therics, Inc. | Rapid prototyping and manufacturing process |
| CN1732899A (en) * | 2005-06-16 | 2006-02-15 | 华中科技大学 | Implantation type local drug delivery device and three-dimensional printing preparation method thereof |
| WO2016116502A1 (en) * | 2015-01-21 | 2016-07-28 | Bayer Oy | Drug delivery system comprising a non-steroidal anti-inflammatory (nsaid) and a progestogenic compound and methods for manufacturing |
Non-Patent Citations (1)
| Title |
|---|
| JEFFERY A WEISMAN ET AL: "Antibiotic and chemotherapeutic enhanced three-dimensional printer filaments and constructs for biomedical applications", 《INTERNATIONAL JOURNAL OF NANOMEDICINE》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727393A (en) * | 2016-12-26 | 2017-05-31 | 浙江工业大学 | A kind of sustained release preparations of ibuprofen containing grid internal structure and preparation method thereof |
| CN108042363A (en) * | 2018-01-17 | 2018-05-18 | 陶俊荣 | One kind can on-line checking Chinese patent medicine tablet preparation system and method |
| US11724486B2 (en) | 2019-07-09 | 2023-08-15 | Kyndryl, Inc. | Printing customized medication based on current user data and medical records of the user |
| CN112618479A (en) * | 2020-11-20 | 2021-04-09 | 扬州大学 | Preparation method of docetaxel/polylactic acid anti-tumor implantation stent |
| CN112618922A (en) * | 2020-12-30 | 2021-04-09 | 上海心至医疗科技有限公司 | Preparation method of drug balloon, prepared drug balloon and application thereof |
| WO2022173227A1 (en) * | 2021-02-10 | 2022-08-18 | 전남대학교 산학협력단 | Method for preparing solid drug formulation on basis of ultraviolet printing |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106109245A (en) | Cancer therapy drug that a kind of 3D of employing printing technique prepares and method | |
| Li et al. | Preparation and investigation of controlled-release glipizide novel oral device with three-dimensional printing | |
| Vaz et al. | 3D printing as a promising tool in personalized medicine | |
| Melocchi et al. | 3D printing by fused deposition modeling (FDM) of a swellable/erodible capsular device for oral pulsatile release of drugs | |
| Kotta et al. | 3D printing technology in drug delivery: recent progress and application | |
| CN103495176B (en) | Method for preparing starch-base soft capsules based on co-blending extrusion method | |
| Samiei | Recent trends on applications of 3D printing technology on the design and manufacture of pharmaceutical oral formulation: a mini review | |
| Zheng et al. | Melt extrusion deposition (MED™) 3D printing technology–A paradigm shift in design and development of modified release drug products | |
| CN103554552B (en) | Preparation process of starch self-reinforced composite material for capsule articles | |
| CN104629161A (en) | Low-melting-point 3D printing material and preparation method thereof | |
| CN107109035A (en) | It is used as the polymer blend of temporary support material in the increasing material manufacturing based on extrusion | |
| Horst | 3D printing of pharmaceutical drug delivery systems | |
| CN103520133A (en) | Preparation method of starch-based soft capsules | |
| Abdella et al. | 3D Printing of thermo-sensitive drugs | |
| Wang et al. | A review of 3D printing technology in pharmaceutics: technology and applications, now and future | |
| EP2865373A1 (en) | Compounding and extruding method for producing starch softgel capsules | |
| CN105687153A (en) | 3D-printing preparation method for tablet medicines through spraying medicaments on matrix material | |
| CN100333712C (en) | Material gradient controlled-release administrating system and its three-dimensional printing-forming preparation method | |
| Su et al. | PLGA sustained-release microspheres loaded with an insoluble small-molecule drug: Microfluidic-based preparation, optimization, characterization, and evaluation in vitro and in vivo | |
| CN101209240B (en) | Medicine gradient zero level implantation controlled-release drug administration device and preparation thereof | |
| Singhvi et al. | 3D-printing: an emerging and a revolutionary technology in pharmaceuticals | |
| Zhao et al. | A new model of a 3D-printed shell with convex drug release profile | |
| CN111840243A (en) | Levetiracetam 3D printing preparation and preparation method thereof | |
| Deshkar et al. | Hot melt extrusion and its application in 3D printing of pharmaceuticals | |
| Bianchi et al. | An overview of poly (vinyl alcohol) and poly (vinyl pyrrolidone) in pharmaceutical additive manufacturing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161116 |
|
| RJ01 | Rejection of invention patent application after publication |